01 January 2000
Antitumor effect of electrochemical therapy on transplantable mouse cancers.
Maciej Wójcicki, Marek Droździk, Sławomir Olewniczak, Adam Opolski, Joanna Wietrzyk, Czesław Radzikowski, Bartosz Kaczmarek, Maciej Wrzesiński, Maciej Romanowski, Marek Kamiński, Stanisław ZielińskiMed Sci Monit 2000; 6(3): BR498-502 :: ID: 421319
Abstract
The aim of our study was to assess the antitumor effect of electrochemicaltherapy (ECT) in the mice bearing advanced transplantable tumours. Mouse mammary cancer 16/C (group 1)and fibrosarcoma F69-3 (group 2) were transplanted subcutaneously (s.c.) into the C3H or BALB/c mice,respectively. Twenty animals in each group bearing measurable s.c. tumours were randomly divided intotwo subgroups (experimental and control). Two electrodes were inserted into tumours and low level directcurrent (6-7 V, 5-21 mA) was passed. The animals were observed and tumors were measured twice a week.The animals were sacrificed and autopsied when the tumor diameter reached 2.0 cm. Two animals of eachgroup (experimental and control) were sacrificed for histopathological tumor examination on the 1st and6th day after ECT. A significant inhibition of tumor growth in mice subjected to ECT was observed, bothin those with s.c. growing mammary cancer and with fibrosarcoma. This inhibition was associated withmarked prolongation of survival time of ECT-treated mice. It appeared that the mice with mammary cancerswere more susceptible to ECT therapy than those with growing s.c. fibrosarcoma. The histopathologicalstudies of tumor specimens from ECT-treated mice showed extensive foci of necrosis with shrinkage ofcell nuclei deprived of chromatin. In conclusion, the treatment which inhibits the growth of experimentalmammary and fibrosarcoma tumors was demonstrated. However, in no mice complete regression of tumourswas observed.
Keywords: Cell Division, Electric Stimulation Therapy, Electrochemistry, Fibrosarcoma, Mammary Neoplasms, Experimental, Mice, Inbred C3H, Neoplasm Transplantation, Time Factors
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Preoperative Blood Transfusion Requirements for Hemorrhoidal Severe Anemia: A Retrospective Study of 128 Pa...Med Sci Monit In Press; DOI: 10.12659/MSM.943126
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952